Riskpilot← Back to searchSign inGet full accessGlycoPharma Holding ApS
APSActiveCVR 39691558Rørhatten 4Activities of holding companies · NACE 6421Est. 2018— employees
Revenue 2025
DKK -13K
-19% vs 2024
EBITDA margin
100.0%
+19% vs 2024
Equity ratio
85.2%
Financial strength
Net profit 2025
DKK -12K
+19% vs 2024
| Revenue | DKK -13K | -19% |
| EBITDA | DKK -13K | +19% |
| Net profit | DKK -12K | +19% |
| Total assets | DKK 803K | +0% |
| Equity | DKK 684K | -2% |
| Employees | — | — |
Legal name
GlycoPharma Holding ApS
CVR number
39691558
Legal form
Anpartsselskab
NACE code
6421 · Activities of holding companies
Founded
28. juni 2018
Share capital
DKK 137.515
Employees
—
VAT registered
No
Audit selected
No
Last report
2025-06-30
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør.
Company purpose
Selskabets formål er at eje aktier og anparter samt enhver virksomhed i hermed stående forbindelse.
Address
Rørhatten 4
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | -8 | -7 | -12 | -8 | -14 | -16 | -13 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -8 | -7 | -12 | -8 | -14 | -16 | -13 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -8 | -7 | -12 | -8 | -14 | -16 | -13 |
| Net financials | 1 | 7 | 2 | -0 | -0 | 0 | 0 |
| Profit before tax | -7 | -1 | -10 | -8 | -14 | -15 | -12 |
| Tax | -1 | -0 | -2 | -1 | -0 | -0 | -0 |
| Net profit | -6 | -1 | -8 | -7 | -14 | -15 | -12 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Total assets | 318 | 405 | 1.044 | 1.433 | 690 | 806 | 803 |
| Equity | 315 | 314 | 414 | 407 | 584 | 697 | 684 |
| Long-term debt | 0 | 0 | 0 | 388 | 0 | 0 | 0 |
| Short-term debt | 4 | 91 | 630 | 638 | 106 | 109 | 119 |
| Total debt | 4 | 91 | 630 | 1.026 | 106 | 109 | 119 |
EBITDA margin
-1252500.0%
This company
15.8%
Market median
-7927315% vs market
20192025
Equity ratio
85.2%
This company
38.2%
Market median
+123% vs market
20192025
Return on equity
-1.8%
This company
18.4%
Market median
-110% vs market
20192025
Net profit margin
-1244100.0%
This company
8.1%
Market median
-15359359% vs market
20192025
Asset turnover
-0.02×
This company
1.12×
Market median
-102% vs market
20192025
Debt / equity
0.17×
This company
0.62×
Market median
+73% vs market
20192025
- Annual report 2025Filed via CVR / Virk · Period 2024-07-01 – 2025-06-30
- Annual report 2024Filed via CVR / Virk · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via CVR / Virk · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via CVR / Virk · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via CVR / Virk · Period 2020-07-01 – 2021-06-30
- Annual report 2020Filed via CVR / Virk · Period 2019-07-01 – 2020-06-30
- Annual report 2019Filed via CVR / Virk · Period 2018-06-28 – 2019-06-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
AB Management | Management | 2018 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Boysen Bio ApS | Company | 33.3% | 33.3% | 2018 |
Zahle Holding ApS | Company | 15.0% | 15.0% | 2018 |
Bioglyco ApS | Company | 10.0% | 10.0% | 2018 |
JMJ Holding ApS | Company | 10.0% | 10.0% | 2018 |
Røssel Invest APS | Company | 10.0% | 10.0% | 2018 |
SCIENCE VENTURES DENMARK A/S | Company | 5.0% | 5.0% | 2018 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Syddansk Universitet (University of Southern Denmark)SCIENCE VENTURES DENMARK A/S
GlycoPharma Holding ApS (this company)Board members of GlycoPharma Holding ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anders Boysen | Management | 0 companies |